This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
respiratory syndrome | 137 |
avian influenza | 102 |
influenza virus | 97 |
syndrome coronavirus | 91 |
middle east | 91 |
acute respiratory | 89 |
public health | 82 |
virus infection | 76 |
east respiratory | 76 |
respiratory viruses | 73 |
zika virus | 73 |
respiratory tract | 68 |
viral rna | 68 |
infectious diseases | 67 |
severe acute | 67 |
novel coronavirus | 66 |
coronavirus hku | 57 |
highly pathogenic | 53 |
influenza viruses | 51 |
neutralizing antibodies | 47 |
porcine deltacoronavirus | 44 |
respiratory disease | 44 |
cord uid | 41 |
doc id | 41 |
viral load | 41 |
infect doi | 41 |
microbes infect | 41 |
emerg microbes | 41 |
amino acid | 40 |
pk cells | 40 |
immune responses | 40 |
monoclonal antibodies | 40 |
st cells | 39 |
immune response | 39 |
united states | 37 |
monoclonal antibody | 36 |
respiratory pathogens | 35 |
antibody responses | 34 |
infected patients | 34 |
nucleic acid | 34 |
respiratory infections | 33 |
emerging infectious | 33 |
infectious disease | 32 |
complete genome | 32 |
performed using | 32 |
control group | 30 |
phylogenetic analysis | 30 |
lung injury | 29 |
hong kong | 29 |
zikv infection | 29 |
infected cells | 28 |
patients infected | 28 |
respiratory virus | 27 |
human monoclonal | 26 |
acute lung | 26 |
saudi arabia | 26 |
human infections | 26 |
clinical signs | 25 |
dengue virus | 25 |
genome sequence | 25 |
closely related | 25 |
ncov rbd | 25 |
west nile | 25 |
disease control | 25 |
three times | 25 |
reverse transcription | 25 |
host cell | 25 |
cell entry | 23 |
health organization | 23 |
goose astrovirus | 23 |
upper respiratory | 23 |
gout disease | 23 |
expression vector | 23 |
innate immune | 23 |
previously described | 22 |
infected goslings | 22 |
target cells | 22 |
anal swab | 21 |
spike protein | 21 |
cell culture | 21 |
viral infection | 21 |
human coronavirus | 21 |
neutralizing antibody | 21 |
pdcov replication | 21 |
diagnostic laboratories | 21 |
negative control | 20 |
fecal samples | 20 |
polymerase chain | 20 |
chain reaction | 20 |
nile virus | 20 |
world health | 20 |
viral infections | 20 |
novel goose | 20 |
respiratory syncytial | 20 |
cell responses | 20 |
time pcr | 20 |
cell fusion | 20 |
lower respiratory | 19 |
oral swabs | 19 |
borne viruses | 19 |
cov strains | 19 |
antiviral mabs | 19 |
tested positive | 19 |
previous studies | 19 |
respiratory symptoms | 19 |
saliva specimens | 19 |
two patients | 19 |
respiratory specimens | 19 |
pathogenic avian | 19 |
phylogenetic tree | 19 |
inflammatory cytokines | 18 |
respiratory infection | 18 |
genetic diversity | 18 |
type i | 18 |
human infection | 18 |
genbank accession | 18 |
cov infection | 18 |
antiviral immune | 18 |
respiratory pathogen | 18 |
epithelial cells | 17 |
potential conflict | 17 |
syncytial virus | 17 |
virus isolation | 17 |
risk factors | 17 |
time rt | 17 |
sars coronavirus | 17 |
liver injury | 17 |
accession number | 17 |
multiplex pcr | 17 |
wild chimpanzees | 17 |
present study | 17 |
virus infections | 17 |
human metapneumovirus | 17 |
viral replication | 17 |
described previously | 16 |
virus replication | 16 |
empty expression | 16 |
health laboratories | 16 |
respiratory viral | 16 |
ebola virus | 16 |
dromedary camels | 16 |
human respiratory | 15 |
supplementary table | 15 |
severe respiratory | 15 |
specific antibodies | 15 |
day post | 15 |
anal swabs | 15 |
respiratory samples | 15 |
hts analysis | 15 |
nipah virus | 15 |
severe cases | 15 |
clinical characteristics | 15 |
cells expressing | 15 |
viral loads | 15 |
well plates | 14 |
swab samples | 14 |
structural proteins | 14 |
western blot | 14 |
weight loss | 14 |
pcr products | 14 |
vero cells | 14 |
serum samples | 14 |
infected individuals | 14 |
neutralizing activity | 14 |
binding domain | 14 |
antiviral response | 14 |
body weight | 14 |
bird markets | 14 |
mers coronavirus | 14 |
severe liver | 14 |
cynomolgus macaques | 13 |
causative agent | 13 |
molecular assays | 13 |
respiratory illness | 13 |
hubei province | 13 |
cellular immune | 13 |
two different | 13 |
tract infections | 13 |
dendritic cells | 13 |
antibody response | 13 |
genome sequences | 13 |
pdcov infection | 13 |
cytokine storm | 13 |
adult patients | 13 |
terminal domain | 13 |
liver impairment | 13 |
nasopharyngeal specimens | 13 |
clinical features | 13 |
viral genome | 13 |
experimental infection | 13 |
novel human | 13 |
receptor binding | 13 |
viral hepatitis | 13 |
binding site | 13 |
transmembrane domains | 13 |
pneumoniae carriage | 13 |
gene sequences | 13 |
effector functions | 13 |
cells transfected | 13 |
coronavirus infection | 12 |
human transmission | 12 |
respiratory distress | 12 |
host range | 12 |
infected mice | 12 |
dna vaccine | 12 |
mutant dpp | 12 |
immune system | 12 |
encephalitis virus | 12 |
pbs bsa | 12 |
time reverse | 12 |
specific antibody | 12 |
coronavirus disease | 12 |
viral respiratory | 12 |
lmh cells | 12 |
irf activation | 12 |
dipeptidyl peptidase | 12 |
confirmed cases | 12 |
nasopharyngeal samples | 12 |
staphylococcus aureus | 12 |
room temperature | 12 |
terminal transmembrane | 12 |
membrane fusion | 12 |
acid residues | 12 |
important role | 12 |
viral pathogens | 12 |
surface expression | 12 |
porcine epidemic | 12 |
oxygen supply | 12 |
pcr assays | 12 |
neutralizing activities | 12 |
novel pathogens | 11 |
potent neutralizing | 11 |
days post | 11 |
cell lines | 11 |
critical role | 11 |
adaptive immune | 11 |
national park | 11 |
human cases | 11 |
spdcov strains | 11 |
pathogenic viruses | 11 |
infected animals | 11 |
viral ha | 11 |
post infection | 11 |
epidemic diarrhea | 11 |
samples collected | 11 |
mouse model | 11 |
influenza infection | 11 |
respiratory diseases | 11 |
pathogen panel | 11 |
pathogenic virus | 11 |
national public | 11 |
respiratory failure | 11 |
dromedary wnv | 11 |
antiviral drugs | 11 |
unexplained pneumonia | 11 |
negative results | 11 |
open reading | 11 |
human antibody | 11 |
previous study | 11 |
phylogenetic trees | 11 |
hypoxic hepatitis | 11 |
innate antiviral | 11 |
severe covid | 11 |
npa specimens | 11 |
parainfluenza virus | 11 |
clinical trials | 11 |
live poultry | 11 |
neutralizing monoclonal | 11 |
complement activation | 11 |
human igg | 11 |
outbreak period | 11 |
south korea | 10 |
deltacoronavirus strain | 10 |
taken together | 10 |
streptococcus pneumoniae | 10 |
cell response | 10 |
dpp wt | 10 |
clinical data | 10 |
effector cells | 10 |
least one | 10 |
acute flaccid | 10 |
within days | 10 |
french pilgrims | 10 |
flow cytometry | 10 |
broadly neutralizing | 10 |
southeast asia | 10 |
catarrhalis carriage | 10 |
symptom onset | 10 |
novel viruses | 10 |
immunofluorescence assay | 10 |
rna virus | 10 |
stranded rna | 10 |
chronic hepatitis | 10 |
neutralizing mabs | 10 |
culture medium | 10 |
orf ab | 10 |
genome sequencing | 10 |
highly similar | 10 |
common cold | 10 |
dpp polymorphisms | 10 |
driven host | 10 |
specific cd | 10 |
reference laboratory | 10 |
bovine serum | 10 |
ifn production | 10 |
nasopharyngeal swabs | 10 |
ncov infection | 10 |
respiratory signs | 10 |
hajj pilgrims | 10 |
cell surface | 10 |
promotes pdcov | 10 |
host species | 10 |
yellow fever | 10 |
trypsin promotes | 10 |
species transmission | 10 |
ng ml | 10 |
relatively low | 10 |
genetic characterization | 10 |
sparrow cov | 10 |
nxtag respiratory | 10 |
pandemic influenza | 10 |
bronchoalveolar lavage | 9 |
immune cells | 9 |
also observed | 9 |
sars patients | 9 |
hajj samples | 9 |
rna extraction | 9 |
virus may | 9 |
ics made | 9 |
results suggest | 9 |
virus rna | 9 |
dpp residues | 9 |
current study | 9 |
primers lpw | 9 |
control groups | 9 |
amino acids | 9 |
possible lrti | 9 |
viral shedding | 9 |
outbreak lineage | 9 |
creative commons | 9 |
goose embryos | 9 |
new coronavirus | 9 |
accessed february | 9 |
tract infection | 9 |
rhinovirus infection | 9 |
even though | 9 |
vaccination strategies | 9 |
chronic respiratory | 9 |
viral challenge | 9 |
patients whose | 9 |
animal models | 9 |
life cycle | 9 |
endemic hcovs | 9 |
influenza vaccine | 9 |
human population | 9 |
phylogenetic analyses | 9 |
old goslings | 9 |
immune complexes | 9 |
sequence alignment | 9 |
secondary antibody | 9 |
dpp expression | 9 |
years old | 9 |
cell lysates | 9 |
lrti symptoms | 9 |
severe patients | 9 |
total rna | 9 |
hbsag anti | 9 |
results indicated | 9 |
family members | 9 |
diarrhea virus | 9 |
ml trypsin | 9 |
applied biosystems | 9 |
severe disease | 9 |
bat origin | 9 |
north america | 9 |
endothelial cells | 9 |
viruses detected | 9 |
poultry workers | 8 |
adhesion molecules | 8 |
immunodeficiency virus | 8 |
college hospital | 8 |
mini kit | 8 |
nucleotide sequence | 8 |
cov rna | 8 |
data analysis | 8 |
statistical significance | 8 |
clinical management | 8 |
new york | 8 |
pneumonia outbreak | 8 |
inhibitory effect | 8 |
heart disease | 8 |
high levels | 8 |
first round | 8 |
expression vectors | 8 |
molecular epidemiology | 8 |
newly identified | 8 |
significant difference | 8 |
lpw lpw | 8 |
crucial role | 8 |
national health | 8 |
clinical samples | 8 |
south america | 8 |
i interferon | 8 |
cell membrane | 8 |
disease outbreak | 8 |
wu polyomavirus | 8 |
neutralization assay | 8 |
luciferase reporter | 8 |
swabs positive | 8 |
mainland china | 8 |
viral entry | 8 |
first time | 8 |
survival rate | 8 |
extracellular traps | 8 |
serological evidence | 8 |
hbv ics | 8 |
nested pcr | 8 |
medical college | 8 |
purified using | 8 |
antigenic drift | 8 |
union medical | 8 |
distress syndrome | 8 |
gosling gout | 8 |
genomic characterization | 8 |
reduced mers | 8 |
cell model | 8 |
great apes | 8 |
clinical symptoms | 8 |
peking union | 8 |
hcv genotypes | 8 |
high prevalence | 8 |
throughput sequencing | 8 |
cov spike | 8 |
dromedary camel | 8 |
mdck cells | 8 |
hku strains | 8 |
health commission | 8 |
acid sequences | 8 |
data suggest | 8 |
buffered saline | 8 |
intensive care | 8 |
tested negative | 8 |
may also | 8 |
transmembrane domain | 8 |
human ace | 8 |
accession numbers | 8 |
hospitalized patients | 8 |
digestive tract | 8 |
saliva samples | 8 |
white blood | 8 |
acquired pneumonia | 8 |
known respiratory | 8 |
close contact | 8 |
neutrophil extracellular | 8 |
round primers | 8 |
viral propagation | 8 |
vaccine development | 8 |
detection rate | 8 |
live bird | 8 |
cov hku | 8 |
peripheral blood | 8 |
arabian peninsula | 8 |
study design | 8 |
pteropine orthoreovirus | 8 |
targeted mabs | 8 |
virus transmission | 8 |
control measures | 8 |
human origin | 8 |
cell line | 8 |
dpp surface | 7 |
asymptomatic cases | 7 |
rapid antigen | 7 |
previous reports | 7 |
cytopathic effects | 7 |
human primates | 7 |
high viral | 7 |
without trypsin | 7 |
new world | 7 |
dual carriage | 7 |
specific rt | 7 |
innate immunity | 7 |
sequence analysis | 7 |
known viral | 7 |
new viruses | 7 |
experimentally infected | 7 |
intermediate host | 7 |
fruit bats | 7 |
length genome | 7 |
positive samples | 7 |
highly divergent | 7 |
human neutralizing | 7 |
luciferase activity | 7 |
sialic acid | 7 |
results show | 7 |
novel hepaciviruses | 7 |
host immune | 7 |
several studies | 7 |
negative controls | 7 |
ethics committee | 7 |
routine clinical | 7 |
immune complex | 7 |
viral transport | 7 |
mean age | 7 |
coronavirus associated | 7 |
asymptomatic carriers | 7 |
respiratory tracts | 7 |
care unit | 7 |
convalescent sera | 7 |
reads mapped | 7 |
whose npa | 7 |
positive rate | 7 |
novel virus | 7 |
results indicate | 7 |
rna polymerase | 7 |
first isolation | 7 |
dpp mutants | 7 |
accessed march | 7 |
pdcov entry | 7 |
cell spread | 7 |
flaccid myelitis | 7 |
hospital stay | 7 |
evolutionary genetics | 7 |
human immunodeficiency | 7 |
generation sequencing | 7 |
new year | 7 |
oxygen saturation | 7 |
dependent manner | 7 |
molecular diagnosis | 7 |
borne encephalitis | 7 |
capsid protein | 7 |
binding affinity | 7 |
clinical specimens | 7 |
neutralizing human | 7 |
severe pneumonia | 7 |
host innate | 7 |
hendra virus | 7 |
international committee | 7 |
viral proteins | 7 |
goose flocks | 7 |
aedes albopictus | 7 |
conjugated anti | 7 |
avian coronaviruses | 7 |
protective effects | 7 |
genbank database | 7 |
comparative analysis | 7 |
hh patients | 7 |
humoral responses | 7 |
potent neutralization | 7 |
significantly reduced | 7 |
inflammatory cells | 7 |
viral clearance | 7 |
protective efficacy | 7 |
calculated accordingly | 7 |
higher viral | 7 |
mice infected | 7 |
tissue tropism | 7 |
coronavirus spike | 7 |
virus shedding | 7 |
hemorrhagic fever | 7 |
previously reported | 7 |
lavage fluid | 7 |
washed three | 7 |
viral diseases | 7 |
cov strain | 7 |
dromedary calf | 7 |
fold increase | 7 |
binding protein | 6 |
median age | 6 |
carriage increased | 6 |
highly conserved | 6 |
viral pathogen | 6 |
present dromedary | 6 |
statistically significant | 6 |
influenza strains | 6 |
serially diluted | 6 |
recent years | 6 |
lung pathology | 6 |
targeted antibodies | 6 |
incubation period | 6 |
reverse transcriptase | 6 |
urate deposition | 6 |
intranasal application | 6 |
transcription polymerase | 6 |
studies demonstrated | 6 |
dna sequencing | 6 |
nucleotide identity | 6 |
disease outbreaks | 6 |
two nasopharyngeal | 6 |
heterologous viruses | 6 |
likelihood method | 6 |
significantly lower | 6 |
ifn antagonism | 6 |
three patients | 6 |
novel avian | 6 |
infection control | 6 |
clinical diagnosis | 6 |
contigs assigned | 6 |
tbk interaction | 6 |
immunized groups | 6 |
icu patients | 6 |
protective immunity | 6 |
genomic sequence | 6 |
emerging viruses | 6 |
specific igg | 6 |
much lower | 6 |
four spdcov | 6 |
significantly higher | 6 |
healthcare workers | 6 |
also detected | 6 |
three groups | 6 |
strain hku | 6 |
body temperature | 6 |
two cases | 6 |
copies ml | 6 |
mammalian species | 6 |
gene source | 6 |
outbreak investigation | 6 |
lane compared | 6 |
immunized three | 6 |
mortality rates | 6 |
chicken astrovirus | 6 |
also identified | 6 |
mild symptoms | 6 |
acid sequence | 6 |
viral sequences | 6 |
analysis revealed | 6 |
detection rates | 6 |
ncov virus | 6 |
lysis buffer | 6 |
second round | 6 |
recent advances | 6 |
humanized anti | 6 |
specimens taken | 6 |
better understanding | 6 |
promoter activity | 6 |
first reported | 6 |
infected pneumonia | 6 |
antigen detection | 6 |
cloacal swabs | 6 |
human rhinovirus | 6 |
viral titers | 6 |
induced acute | 6 |
constructed using | 6 |
vesicular stomatitis | 6 |
antiviral treatment | 6 |
interspecies transmission | 6 |
pbs containing | 6 |
ns protein | 6 |
transport medium | 6 |
national reference | 6 |
variant sites | 6 |
clinical disease | 6 |
nonhuman primates | 6 |
strains circulating | 6 |
pcr using | 6 |
informed consent | 6 |
african green | 6 |
thermofisher scientific | 6 |
molecular evolutionary | 6 |
torque teno | 6 |
error bars | 6 |
molecular characterization | 6 |
relatively high | 6 |
blot analysis | 6 |
syndrome virus | 6 |
million reads | 6 |
outbreak associated | 6 |
neurological symptoms | 6 |
high level | 6 |
carcass wash | 6 |
wuhan institute | 6 |
first isolated | 6 |
south china | 6 |
japanese encephalitis | 6 |
wnv strains | 6 |
kibale national | 6 |
stomatitis virus | 6 |
highly neutralizing | 6 |
epidemic season | 6 |
case group | 6 |
antibodies targeting | 6 |
analytical diagnostic | 6 |
chimpanzee communities | 6 |
reading frames | 6 |
cell types | 6 |
disease severity | 6 |
prospective cohort | 6 |
way analysis | 6 |
young children | 6 |
recent study | 6 |
superscript iii | 6 |
test results | 6 |
throat swab | 6 |
mosquito species | 6 |
reverse primers | 6 |
apn cells | 6 |
also showed | 6 |
fever virus | 6 |
organ failure | 6 |
wash water | 6 |
influenza vaccines | 6 |
poultry markets | 6 |
sample collection | 6 |
low pathogenic | 6 |
intranasal administration | 6 |
disposable handkerchiefs | 6 |
related coronavirus | 6 |
died within | 6 |
pcr system | 6 |
bd biosciences | 6 |
virus entry | 6 |
mortality rate | 6 |
also demonstrated | 6 |
human populations | 6 |
rna viruses | 6 |
pcr detection | 6 |
denv ediii | 6 |
tract specimens | 6 |
genetically distinct | 6 |
guangdong province | 6 |
blood cell | 6 |
cov rbd | 6 |
antibodies isolated | 6 |
tissue samples | 6 |
expectorated saliva | 6 |
goose parvovirus | 6 |
complement system | 6 |
human coronaviruses | 6 |
conserved regions | 6 |
first cohort | 6 |
diagnostic testing | 6 |
clinical manifestations | 6 |
emerging infections | 6 |
novel astrovirus | 6 |
virus detection | 6 |
least two | 6 |
sequence data | 6 |
bacterial infection | 6 |
hemorrhagic polyomavirus | 5 |
much higher | 5 |
human enterovirus | 5 |
virus detected | 5 |
avian astroviruses | 5 |
cellular receptor | 5 |
specimens collected | 5 |
novel genotype | 5 |
sendai virus | 5 |
panel assay | 5 |
ali induced | 5 |
aastv sd | 5 |
cause respiratory | 5 |
strains isolated | 5 |
lung diseases | 5 |
reduced lung | 5 |
immunosuppressive activity | 5 |
systematic review | 5 |
therapeutic potential | 5 |
french polynesia | 5 |
disease progression | 5 |
standard precautions | 5 |
nasopharyngeal aspirate | 5 |
pharyngeal swab | 5 |
avian nephritis | 5 |
san diego | 5 |
pathogen detection | 5 |
receptor dpp | 5 |
illness associated | 5 |
therapeutic vaccine | 5 |
complete blood | 5 |
flaviviridae family | 5 |
antiviral immunity | 5 |
neutralization activities | 5 |
three mabs | 5 |
showed positive | 5 |
positive results | 5 |
critically ill | 5 |
oral swab | 5 |
descriptive study | 5 |
simultaneous detection | 5 |
genus pegivirus | 5 |
among hajj | 5 |
different types | 5 |
new insights | 5 |
clinical laboratory | 5 |
polymorphic sites | 5 |
acid test | 5 |
urine samples | 5 |
disease emergence | 5 |
vast majority | 5 |
acid amplification | 5 |
antibiotic use | 5 |
diseased goslings | 5 |
alternatively known | 5 |
zikv isolates | 5 |
bat coronaviruses | 5 |
reference sequences | 5 |
goat anti | 5 |
shandong province | 5 |
zikv strain | 5 |
health laboratory | 5 |
haemophilus influenzae | 5 |
early stage | 5 |
responses among | 5 |
lpai viruses | 5 |
multiple sequence | 5 |
polymorphic residues | 5 |
binding activity | 5 |
newly discovered | 5 |
sanger sequencing | 5 |
associated coronavirus | 5 |
aa identity | 5 |
gene expression | 5 |
infectious agents | 5 |
septic shock | 5 |
mouse igg | 5 |
data collection | 5 |
time points | 5 |
converting enzyme | 5 |
wild apes | 5 |
cov antibodies | 5 |
ncov may | 5 |
genome analysis | 5 |
lr region | 5 |
liver function | 5 |
derived viruses | 5 |
human disease | 5 |
affiliated hospital | 5 |
acute infection | 5 |
wild birds | 5 |
infected llc | 5 |
science foundation | 5 |
viral antigen | 5 |
positive control | 5 |
lunar new | 5 |
agnostic hts | 5 |
arbovirus control | 5 |
ics formed | 5 |
reading frame | 5 |
cov infections | 5 |
treatment options | 5 |
rna levels | 5 |
primary antibody | 5 |
viral diversity | 5 |
trypsin treatment | 5 |
hek cells | 5 |
species barrier | 5 |
two weeks | 5 |
successfully isolated | 5 |
ill patients | 5 |
human antibodies | 5 |
fc binding | 5 |
reassortment events | 5 |
tested using | 5 |
infectious sars | 5 |
novel coronaviruses | 5 |
astrovirus associated | 5 |
illness day | 5 |
rna genome | 5 |
blood cells | 5 |
different mammalian | 5 |
neonatal scid | 5 |
virus neutralization | 5 |
cells infected | 5 |
emerging viral | 5 |
acid substitutions | 5 |
ns gene | 5 |
protein expression | 5 |
cultured cells | 5 |
pathogen carriage | 5 |
human influenza | 5 |
disease association | 5 |
dengue fever | 5 |
aedes aegypti | 5 |
virus challenge | 5 |
diabetes mellitus | 5 |
protective equipment | 5 |
pretreated groups | 5 |
high degree | 5 |
testing positive | 5 |
preventive measures | 5 |
global health | 5 |
gb virus | 5 |
centre cohort | 5 |
animal model | 5 |
may lead | 5 |
post transfection | 5 |
ediii protein | 5 |
oropharyngeal swabs | 5 |
infections among | 5 |
virus isolated | 5 |
expression plasmids | 5 |
using quantitative | 5 |
oxidative burst | 5 |
per person | 5 |
fatality rate | 5 |
healthy individuals | 5 |
wnv genome | 5 |
blood count | 5 |
ge healthcare | 5 |
virus taxonomy | 5 |
scid mice | 5 |
acid extraction | 5 |
biological activities | 5 |
nelson bay | 5 |
nphv variants | 5 |
mg kg | 5 |
among pilgrims | 5 |
uninfected control | 5 |
bat sars | 5 |
recent studies | 5 |
health reference | 5 |
liver disease | 5 |
moraxella catarrhalis | 5 |
pathogenic viral | 5 |
copies per | 5 |
antiviral antibodies | 5 |
antiviral drug | 5 |
zikv rna | 5 |
nasopharyngeal aspirates | 5 |
calculated using | 5 |
different mers | 5 |
leading cause | 5 |
via two | 5 |
nasal swab | 5 |
proinflammatory cytokines | 5 |
infect humans | 5 |
low levels | 5 |
encoded proteins | 5 |
health care | 5 |
passive immunotherapies | 5 |
viral genomes | 5 |
ace receptor | 5 |
diagnostic methods | 5 |
oral fluid | 5 |
old female | 5 |
second part | 5 |
npa samples | 5 |
flaccid paralysis | 5 |
clinical testing | 5 |
respiratory illnesses | 5 |
virus associated | 5 |
goose hemorrhagic | 5 |
expression plasmid | 5 |
cov replication | 5 |
mice immunized | 5 |
small animal | 5 |
human viruses | 5 |
life technologies | 5 |
personal protective | 5 |
test whether | 5 |
clinical microbiology | 5 |
rectal swabs | 5 |
na sequences | 5 |
type diabetes | 5 |
provided evidence | 5 |
analyzed using | 5 |
acute severe | 5 |
functional receptor | 5 |
mers coronaviruses | 5 |
human poscv | 5 |
origin influenza | 5 |
inflammatory response | 5 |
statistical analysis | 5 |
clinical findings | 5 |
viral titer | 5 |
chinese academy | 5 |
ha proteins | 5 |
emerging microbes | 5 |
infection model | 5 |
study group | 5 |
healthy control | 5 |
microbiology laboratory | 5 |
might also | 5 |
pan troglodytes | 5 |
viral spike | 5 |
lbm workers | 5 |
left ventricular | 5 |
virus outbreak | 5 |
coding region | 5 |
may play | 5 |
ifn expression | 5 |
transmission dynamics | 5 |
infection among | 5 |
loading control | 5 |
circular virus | 5 |
antiviral responses | 5 |
light chain | 5 |
step rt | 5 |
genetics analysis | 5 |
zoonotic transmission | 5 |
virus type | 5 |
like circular | 5 |
like viruses | 5 |
astrovirus gd | 5 |
complete genomes | 5 |
avian species | 5 |
infection study | 5 |
large number | 5 |
late stage | 5 |
liver tissue | 4 |
suspected respiratory | 4 |
gene sequence | 4 |
molecular diagnostics | 4 |
mortem biopsy | 4 |
transmit arboviruses | 4 |
metapneumovirus infection | 4 |
group immunized | 4 |
scid beige | 4 |
respiratory infectious | 4 |
virus spread | 4 |
graphpad prism | 4 |
reported cases | 4 |
data indicate | 4 |
single polyprotein | 4 |
water samples | 4 |
efficiently isolated | 4 |
renal tubules | 4 |
nucleotide sequences | 4 |
minimum essential | 4 |
veterinary research | 4 |
syncytium formation | 4 |
lung viral | 4 |
imported cases | 4 |
mortem analysis | 4 |
study also | 4 |
swab positive | 4 |
epidemiological studies | 4 |
otitis media | 4 |
strains identified | 4 |
universal vaccine | 4 |
pooled liver | 4 |
early response | 4 |
recently identified | 4 |
domestic animals | 4 |
coronavirus oc | 4 |
increase virus | 4 |
pcr panel | 4 |
tissue damage | 4 |
ic values | 4 |
chikungunya virus | 4 |
clinical course | 4 |
untranslated region | 4 |
solid matrix | 4 |
infected birds | 4 |
adapter protein | 4 |
zikv isolated | 4 |
hepatitis virus | 4 |
cohort study | 4 |
nucleocapsid protein | 4 |
public databases | 4 |
laser scanning | 4 |
astv infection | 4 |
marburg virus | 4 |
ncov spike | 4 |
virus species | 4 |
also shown | 4 |
human parainfluenza | 4 |
detection assay | 4 |
progressive multifocal | 4 |
three distinct | 4 |
analysis using | 4 |
vector transmission | 4 |
like coronavirus | 4 |
remains unclear | 4 |
commons attribution | 4 |
nasopharyngeal swab | 4 |
nine children | 4 |
cd cd | 4 |
bacterial respiratory | 4 |
expression levels | 4 |
united arab | 4 |
may result | 4 |
na genes | 4 |
control strategies | 4 |
considered statistically | 4 |
ectopically expressed | 4 |
pdcov strains | 4 |
two days | 4 |
results showed | 4 |
urgently needed | 4 |
sequence identity | 4 |
neurological complications | 4 |
sequence diversity | 4 |
like effects | 4 |
sangon biotech | 4 |
kidney function | 4 |
patients admitted | 4 |
emerging human | 4 |
multiple clades | 4 |
nasal swabs | 4 |
infection may | 4 |
parainfluenza viruses | 4 |
bovine cov | 4 |
significant differences | 4 |
one step | 4 |
antibody titer | 4 |
viral panel | 4 |
matched healthy | 4 |
testing saliva | 4 |
green monkeys | 4 |
visceral urate | 4 |
temperate regions | 4 |
isolation rates | 4 |
nervous system | 4 |
drinking water | 4 |
environmental samples | 4 |
nasopharyngeal strains | 4 |
mm hg | 4 |
fisher scientific | 4 |
molecular detection | 4 |
liver enzymes | 4 |
coronavirus quasispecies | 4 |
respiratory secretions | 4 |
homologous virus | 4 |
potential therapeutic | 4 |
samples tested | 4 |
first affiliated | 4 |
peptidase iv | 4 |
specimens tested | 4 |
novel viral | 4 |
binding activities | 4 |
cause disease | 4 |
vaccinated mice | 4 |
newly emerging | 4 |
severe clinical | 4 |
xtag respiratory | 4 |
genomic rna | 4 |
hbv infection | 4 |
structural basis | 4 |
jiangsu province | 4 |
north africa | 4 |
virus circulation | 4 |
positive respiratory | 4 |
luminex xtag | 4 |
quantitative rt | 4 |
recombinant protein | 4 |
whole blood | 4 |
vaccine design | 4 |
different epitopes | 4 |
disease surveillance | 4 |
investigated whether | 4 |
fc receptors | 4 |
genetically diverse | 4 |
clinical practice | 4 |
infected group | 4 |
virus pathogenesis | 4 |
mucosal adjuvant | 4 |
transmission caused | 4 |
urate deposits | 4 |
authentic mers | 4 |
plasma membrane | 4 |
reported previously | 4 |
multiplex reverse | 4 |
immunosorbent assay | 4 |
lethal infection | 4 |
cultivated without | 4 |
mfi value | 4 |
genetic variation | 4 |
clinical trial | 4 |
tract disease | 4 |
zikv ediii | 4 |
binding pocket | 4 |
pcr amplification | 4 |
within week | 4 |
infectious virus | 4 |
confocal laser | 4 |
fourth passage | 4 |
mediated protection | 4 |
goose embryo | 4 |
ek peptide | 4 |
npa sample | 4 |
viruses might | 4 |
cytokines including | 4 |
related hepaciviral | 4 |
ventricular failure | 4 |
virus infected | 4 |
one adult | 4 |
putative ns | 4 |
productive cough | 4 |
transmissible gastroenteritis | 4 |
control study | 4 |
using first | 4 |
related viruses | 4 |
hiv infection | 4 |
liver transplantation | 4 |
previously identified | 4 |
emerging arboviruses | 4 |
determined using | 4 |
individual preventive | 4 |
another group | 4 |
probable bat | 4 |
png sites | 4 |
pcr assay | 4 |
mice treated | 4 |
thermo fisher | 4 |
severe viral | 4 |
lung samples | 4 |
oxygen therapy | 4 |
pcr product | 4 |
health concern | 4 |
two strains | 4 |
next pandemic | 4 |
like illness | 4 |
unknown etiology | 4 |
respiratory coronavirus | 4 |
natural science | 4 |
potential role | 4 |
antiviral cytokines | 4 |
lymphocyte subsets | 4 |
southern china | 4 |
february th | 4 |
severe influenza | 4 |
immunized mice | 4 |
healthy animals | 4 |
respiratory panel | 4 |
vitro studies | 4 |
necrosis factor | 4 |
salt bridge | 4 |
elevated liver | 4 |
flow cytometer | 4 |
based vaccine | 4 |
pediatric patients | 4 |
fatal infection | 4 |
chronic obstructive | 4 |
th th | 4 |
linked glycosylation | 4 |
dna vaccination | 4 |
human diseases | 4 |
rna kit | 4 |
chronic heart | 4 |
vaccine based | 4 |
syndrome caused | 4 |
collection method | 4 |
internal genes | 4 |
previously established | 4 |
lower identity | 4 |
important implications | 4 |
interquartile range | 4 |
shm rates | 4 |
transcription factor | 4 |
zikv strains | 4 |
deutsche forschungsgemeinschaft | 4 |
rdrp gene | 4 |
cells via | 4 |
injury induced | 4 |
least three | 4 |
chronic viral | 4 |
sequence homology | 4 |
electron microscopy | 4 |
suckling mice | 4 |
microcephaly cases | 4 |
novel group | 4 |
serine protease | 4 |
increased levels | 4 |
increased circulation | 4 |
membrane attack | 4 |
genus deltacoronavirus | 4 |
conjugated secondary | 4 |
two independent | 4 |
antibody targeting | 4 |
airborne transmission | 4 |
whether trypsin | 4 |
primate species | 4 |
simultaneous outbreaks | 4 |
pcr testing | 4 |
transmembrane protein | 4 |
reduced binding | 4 |
infected humans | 4 |
intense circulation | 4 |
firefly luciferase | 4 |
preclinical models | 4 |
anthroponotic transmission | 4 |
saliva specimen | 4 |
new virus | 4 |
viral nucleotide | 4 |
extracellular histones | 4 |
ncov infected | 4 |
tembusu virus | 4 |
per ml | 4 |
commons license | 4 |
envelope proteins | 4 |
blastn analysis | 4 |
specific human | 4 |
animal reservoir | 4 |
binding studies | 4 |
igg antibodies | 4 |
natural reservoirs | 4 |
obstructive pulmonary | 4 |
one patient | 4 |
cell migration | 4 |
reporter assay | 4 |
additional data | 4 |
expressing dpp | 4 |
genomic region | 4 |
samples using | 4 |
kidney cells | 4 |
infect eukaryotic | 4 |
isolated virus | 4 |
excluded based | 4 |
strains share | 4 |
common pathogens | 4 |
secondary bacterial | 4 |
positive animals | 4 |
genetic relatedness | 4 |
detection positive | 4 |
final extension | 4 |
sterile pbs | 4 |
inoculated onto | 4 |
neutralizing mab | 4 |
viruses using | 4 |
nonhuman primate | 4 |
empty pvax | 4 |
slightly higher | 4 |
lung infiltration | 4 |
animal care | 4 |
multifocal leukoencephalopathy | 4 |
samples positive | 4 |
integrated system | 4 |
respiratory swab | 4 |
epitope region | 4 |
recent report | 4 |
antigen presentation | 4 |
vp region | 4 |
human polyomavirus | 4 |
serum viral | 4 |
early detection | 4 |
hku may | 4 |
specific pathogen | 4 |
blood samples | 4 |
proteins ns | 4 |
neutralization activity | 4 |
among rural | 4 |
unexplained cases | 4 |
thank dr | 4 |
rna extracted | 4 |
essential medium | 4 |
soil mud | 4 |
old world | 4 |
using lipofectamine | 4 |
pulmonary disease | 4 |
one case | 4 |
early transmission | 4 |
health diagnostic | 4 |
neuraminidase inhibitors | 4 |
influenza pandemic | 4 |
chronic hiv | 4 |
np swab | 4 |
pegivirus genus | 4 |
investigate whether | 4 |
methods section | 4 |
zoonotic viruses | 4 |
well plate | 4 |
nonstructural proteins | 4 |
first transmembrane | 4 |
three animals | 4 |
asian countries | 4 |
maximum likelihood | 4 |
medical personnel | 4 |
indicated concentrations | 4 |
eukaryotic organisms | 4 |
transcription pcr | 4 |
independent experiments | 4 |
qiaamp viral | 4 |
spdcov isu | 4 |
structural region | 4 |
soluble mers | 4 |
domain complexed | 4 |
antibody effector | 4 |
univariable analysis | 4 |
specimen types | 4 |
coronavirus infections | 4 |
human dpp | 4 |
infected mdck | 4 |
myocardial infarction | 4 |
rna copies | 4 |
social groups | 4 |
quantitative pcr | 4 |
two distinct | 4 |
tissue culture | 4 |
first part | 4 |
detectable viral | 4 |
rna mini | 4 |
pretreated group | 4 |
int emergencies | 4 |
conjugated goat | 4 |
kanyawara chimpanzees | 4 |
cellular entry | 4 |
suppressive effect | 4 |
imported case | 4 |
positive result | 4 |
serum sample | 4 |
fc fragment | 4 |
pneumococcal vaccine | 4 |
cell counts | 4 |
therapeutic efficacy | 4 |
i ifn | 4 |
gout symptom | 4 |
ct value | 4 |
directly interact | 4 |
diagnostic assays | 4 |
zikv prm | 4 |
african continent | 4 |
causes severe | 4 |
inflammatory cell | 4 |
dna vaccines | 4 |
teno virus | 4 |
quantitative real | 4 |
nucleic acids | 4 |
novel pathogen | 4 |
global trends | 4 |
dependent enhancement | 4 |
attack complex | 4 |
coronavirus study | 4 |
among french | 4 |
based vaccination | 4 |
linked immunosorbent | 4 |
neutralizing epitopes | 4 |
laboratory system | 4 |
protease tmprss | 4 |
poultry drinking | 4 |
nephritis virus | 4 |
clinical manifestation | 4 |
porcine respiratory | 4 |
targeted mab | 4 |
pilgrims presented | 4 |
analyses revealed | 4 |
determine whether | 4 |
potent human | 4 |
antigen specific | 4 |
arab emirates | 4 |
analysis based | 3 |
arbovirus diseases | 3 |
new host | 3 |
serological testing | 3 |
interferon antagonist | 3 |
gov coronavirus | 3 |
chronic liver | 3 |
modified eagle | 3 |
control goslings | 3 |
will also | 3 |
induced activation | 3 |
partially supported | 3 |
infected monkeys | 3 |
duck astrovirus | 3 |
genome characterization | 3 |
transgenic mice | 3 |
binding ability | 3 |
last two | 3 |
cells using | 3 |
significant increase | 3 |
protein bands | 3 |
laboratory test | 3 |
constructed two | 3 |
female balb | 3 |
malaysian ev | 3 |
viral genomic | 3 |
mycobacterium tuberculosis | 3 |
cov neutralizing | 3 |
pcr plates | 3 |
supports bat | 3 |
trypsin significantly | 3 |
immune dysfunction | 3 |
endotracheal intubation | 3 |
health analytical | 3 |
neutralization test | 3 |
wt prm | 3 |
natural infection | 3 |
zikv gz | 3 |
ground glass | 3 |
oral transmission | 3 |
related virus | 3 |
reactive antibodies | 3 |
pathogenic arboviruses | 3 |
coding sequence | 3 |
allowed us | 3 |
strain ch | 3 |
persistent viral | 3 |
cell proliferation | 3 |
required admission | 3 |
molecular mechanisms | 3 |
rhesus monkeys | 3 |
protein sequence | 3 |
multiplex rt | 3 |
future studies | 3 |
bars indicating | 3 |
klebsiella pneumoniae | 3 |
pcr rt | 3 |
immunization groups | 3 |
virus using | 3 |
dpp ectodomain | 3 |
remain unexplained | 3 |
effective treatment | 3 |
pelleted cells | 3 |
approximately weeks | 3 |
guangdong sf | 3 |
based assay | 3 |
tree based | 3 |
respiratory outbreaks | 3 |
induce higher | 3 |
study showed | 3 |
reassortant strains | 3 |
respiratory bacteria | 3 |
influenza infections | 3 |
emerging pathogens | 3 |
patients showed | 3 |
incremental benefit | 3 |
nt long | 3 |
genetic distance | 3 |
trachea lung | 3 |
different countries | 3 |
health measures | 3 |
specimen type | 3 |
induced liver | 3 |
higher frequency | 3 |
multiple shedding | 3 |
related wnv | 3 |
using standard | 3 |
tract might | 3 |
individual pneumonia | 3 |
agents causing | 3 |
diseases will | 3 |
mutual association | 3 |
type ii | 3 |
epidemiological history | 3 |
ncov infections | 3 |
atypical pneumonia | 3 |
genetic heterogeneity | 3 |
survival geese | 3 |
inflammatory mediators | 3 |
human betacoronavirus | 3 |
dependent phosphorylation | 3 |
general medical | 3 |
common cause | 3 |
escape mutants | 3 |
collected samples | 3 |
wildlife species | 3 |
nuclear factor | 3 |
coronavirus pneumonia | 3 |
two sars | 3 |
showed potent | 3 |
another zoonotic | 3 |
africa exhibit | 3 |
aspartate aminotransferase | 3 |
case reports | 3 |
among covid | 3 |
central china | 3 |
diva software | 3 |
national science | 3 |
lung inflammation | 3 |
testing showed | 3 |
mem medium | 3 |
robust immunocompetent | 3 |
routine diagnostic | 3 |
homologous influenza | 3 |
infectious agent | 3 |
bootstrap values | 3 |
animal health | 3 |
wide range | 3 |
polymorphic dpp | 3 |
rti symptoms | 3 |
discharged children | 3 |
metagenomic analysis | 3 |
betacoronavirus causing | 3 |
virus particles | 3 |
bat species | 3 |
asymptomatic infections | 3 |
western blotting | 3 |
ongoing gosling | 3 |
seven novel | 3 |
human bocavirus | 3 |
enteric infections | 3 |
side chain | 3 |
operational recommendation | 3 |
detailed information | 3 |
largest single | 3 |
relative binding | 3 |
ics composed | 3 |
developing neutralizing | 3 |
sputum production | 3 |
virus genome | 3 |
independent positive | 3 |
national research | 3 |
rapid detection | 3 |
expectorate saliva | 3 |
motif nys | 3 |
african strain | 3 |
one horse | 3 |
mutation rates | 3 |
specimen collection | 3 |
uninfected cells | 3 |
cause human | 3 |
surveillance study | 3 |
disease caused | 3 |
antagonizing activity | 3 |
induced high | 3 |
pan american | 3 |
research laboratory | 3 |
cells reached | 3 |
metagenomic sequencing | 3 |
immunofluorescent assay | 3 |
pediatric respiratory | 3 |
biological inc | 3 |
pcr amplifications | 3 |
significantly increased | 3 |
porcine aminopeptidase | 3 |
causing sars | 3 |
centralized national | 3 |
technology major | 3 |
structural analysis | 3 |
protein binding | 3 |
obtained using | 3 |
chemotactic activity | 3 |
two pathways | 3 |
might provide | 3 |
combined data | 3 |
stool showed | 3 |
chn sd | 3 |
collection devices | 3 |
therapeutic antibodies | 3 |
infection caused | 3 |
recovered patients | 3 |
near full | 3 |
cell lysate | 3 |
oseltamivir treatment | 3 |
laboratory animal | 3 |
routinely used | 3 |
fluorescent signals | 3 |
three novel | 3 |
prospective study | 3 |
crossspecies transmission | 3 |
novel monoclonal | 3 |
mountain gorillas | 3 |
proinflammatory mediators | 3 |
geographic area | 3 |
antigen complexes | 3 |
wuhan china | 3 |
dna library | 3 |
hospitalization among | 3 |
centrilobular necrosis | 3 |
like particles | 3 |
aiv circulation | 3 |
mosquito bites | 3 |
one respiratory | 3 |
among different | 3 |
mean time | 3 |
body weights | 3 |
substitution model | 3 |
throat swabs | 3 |
three hpai | 3 |
lung damage | 3 |
eagle medium | 3 |
confirmed human | 3 |
germline sequences | 3 |
fatal case | 3 |
porcine deltacoronaviruses | 3 |
quality control | 3 |
death occurred | 3 |
also reduced | 3 |
two pathogens | 3 |
necrotic cells | 3 |
adhesion molecule | 3 |
mammalian viruses | 3 |
dependent rna | 3 |
shed light | 3 |
bluetongue virus | 3 |
visit http | 3 |
maintenance optimum | 3 |
groups immunized | 3 |
arthropod species | 3 |
central veterinary | 3 |
renal failure | 3 |
genome level | 3 |
washed times | 3 |
crystal structure | 3 |
acid changes | 3 |
mountain gorilla | 3 |
gastroenteritis virus | 3 |
hh cases | 3 |
ics might | 3 |
respiratory microbiota | 3 |
using mega | 3 |
molecular diagnostic | 3 |
old male | 3 |
positive mutual | 3 |
among patients | 3 |
mab hnigga | 3 |
lysosomal proteases | 3 |
complex interactions | 3 |
cholera toxin | 3 |
twice daily | 3 |
phnom penh | 3 |
conferred protection | 3 |
five epidemic | 3 |
pdm virus | 3 |
since december | 3 |
diseased gosling | 3 |
specific antiviral | 3 |
antibody titres | 3 |
diagnostic laboratory | 3 |
fatal outcome | 3 |
swine enteric | 3 |
centrilobular liver | 3 |
previous publications | 3 |
express flow | 3 |
molecular devices | 3 |
vp gene | 3 |
sequence similarity | 3 |
mice pretreated | 3 |
negative pressure | 3 |
intermediate hosts | 3 |
programmed death | 3 |
gombe national | 3 |
old man | 3 |
regulatory factor | 3 |
vp vp | 3 |
antibiotic intake | 3 |
ccid ml | 3 |
cell priming | 3 |
coronavirus isolated | 3 |
cytopathic effect | 3 |
increasing number | 3 |
pathogen identification | 3 |
org licenses | 3 |
arbovirus disease | 3 |
mycoplasma pneumoniae | 3 |
heavy chain | 3 |
immune effects | 3 |
hrv carriage | 3 |
viral identifications | 3 |
graphpad software | 3 |
detect viral | 3 |
sore throat | 3 |
accessory proteins | 3 |
clinical syndromes | 3 |
viruses clustered | 3 |
free radicals | 3 |
dpp interaction | 3 |
serological investigation | 3 |
published previously | 3 |
two years | 3 |
human immunoglobulin | 3 |
dhbsag anti | 3 |
fecal sample | 3 |
naturally infected | 3 |
etiological agent | 3 |
fecal intestinal | 3 |
different animals | 3 |
autoimmune diseases | 3 |
viral envelope | 3 |
unique amino | 3 |
every year | 3 |
also associated | 3 |
deleterious effects | 3 |
goose chn | 3 |
virus testing | 3 |
large social | 3 |
studies will | 3 |
already known | 3 |
avian astrovirus | 3 |
protein encoded | 3 |
major project | 3 |
longitudinal human | 3 |
creatine kinase | 3 |
patient infected | 3 |
next investigated | 3 |
virus titer | 3 |
human exposure | 3 |
identifications made | 3 |
passive immunotherapy | 3 |
laboratory animals | 3 |
different parts | 3 |
positive patients | 3 |
special collection | 3 |
bars indicate | 3 |
sparrow fecal | 3 |
mn chimera | 3 |
rift valley | 3 |
high titer | 3 |
inflammatory responses | 3 |
like sars | 3 |
initial virus | 3 |
hepatocellular carcinoma | 3 |
protein sequences | 3 |
domestic poultry | 3 |
alveolar macrophages | 3 |
prv infection | 3 |
animal species | 3 |
nt orf | 3 |
rna concentrations | 3 |
wide variety | 3 |
virus titre | 3 |
chest radiography | 3 |
chorioallantoic membrane | 3 |
low level | 3 |
primer pairs | 3 |
susceptible cells | 3 |
respiratory agents | 3 |
widely detected | 3 |
zoonotic betacoronavirus | 3 |
daily transmission | 3 |
terminal cmyc | 3 |
three infected | 3 |
zoonotic infection | 3 |
based elisa | 3 |
develop vaccines | 3 |
ha protein | 3 |
simian immunodeficiency | 3 |
syncytial viruses | 3 |
sequence reads | 3 |
intravenous immunoglobulin | 3 |
log copies | 3 |
may increase | 3 |
avian flu | 3 |
cell type | 3 |
coronavirus sars | 3 |
molecular epidemiological | 3 |
new species | 3 |
thermal cycler | 3 |
disease spectrum | 3 |
amplified using | 3 |
avian astv | 3 |
common ancestry | 3 |
sequence variants | 3 |
many cases | 3 |
induced ali | 3 |
horseradish peroxidase | 3 |
ha genes | 3 |
human whole | 3 |
detectable virus | 3 |
rapid development | 3 |
stool samples | 3 |
species isolated | 3 |
enterovirus surveillance | 3 |
shedding routes | 3 |
research council | 3 |
passive immunization | 3 |
subgenus sarbecovirus | 3 |
respiratory papillomatosis | 3 |
afp cases | 3 |
first case | 3 |
virus lifecycle | 3 |
vertebrate host | 3 |
body fluids | 3 |
may serve | 3 |
host cells | 3 |
activated product | 3 |
immunocompetent small | 3 |
tumor necrosis | 3 |
present wnv | 3 |
usa ia | 3 |
promote pdcov | 3 |
collected days | 3 |
severe symptoms | 3 |
measured using | 3 |
cellular receptors | 3 |
previously characterized | 3 |
zikv genomic | 3 |
four successive | 3 |
gel electrophoresis | 3 |
syndrome outbreak | 3 |
multiple avian | 3 |
ev species | 3 |
pdcov real | 3 |
transmission efficiency | 3 |
nonstructural protein | 3 |
specific primers | 3 |
induce stronger | 3 |
medical ward | 3 |
less likely | 3 |
epidemic waves | 3 |
particular modifications | 3 |
particular concern | 3 |
viral rnas | 3 |
alere i | 3 |
infected via | 3 |
hku infection | 3 |
randomly selected | 3 |
high proportion | 3 |
naturally occurring | 3 |
fcs express | 3 |
molecular testing | 3 |
saharan africa | 3 |
diseases caused | 3 |
shedding detection | 3 |
also discussed | 3 |
pneumonia cases | 3 |
emerging hpai | 3 |
zikv mabs | 3 |
institutional animal | 3 |
saliva collected | 3 |
risk factor | 3 |
rna shedding | 3 |
chicken swabs | 3 |
renal tubular | 3 |
conducted among | 3 |
swab cohort | 3 |
ch sichuan | 3 |
dramatic increase | 3 |
arboviral diseases | 3 |
antiviral therapy | 3 |
east asia | 3 |
binding kinetics | 3 |
highly contagious | 3 |
common ancestor | 3 |
biotech co | 3 |
frequent cause | 3 |
sh strain | 3 |
pulmonary consolidation | 3 |
molecular clock | 3 |
clinical observation | 3 |
prior exposure | 3 |
histologic examination | 3 |
recognized residues | 3 |
spike receptor | 3 |
analysis version | 3 |
low prevalence | 3 |
viral pneumonia | 3 |
isothermal amplification | 3 |
ngogo chimpanzees | 3 |
endothelial cell | 3 |
related hepatitis | 3 |
envelope gp | 3 |
kindly provided | 3 |
serological surveys | 3 |
viral antigens | 3 |
hospitalized adult | 3 |
interferon production | 3 |
roche diagnostics | 3 |
emergencies diseases | 3 |
lsr ii | 3 |
diverse mammalian | 3 |
purification kit | 3 |
stranded dna | 3 |
prolonged viral | 3 |
health capacity | 3 |
coronavirus receptor | 3 |
culture supernatant | 3 |
table shows | 3 |
pilgrims reported | 3 |
endogenous antiviral | 3 |
circulatory failure | 3 |
serum albumin | 3 |
mediated release | 3 |
frequently detected | 3 |
largely due | 3 |
apparently healthy | 3 |
also revealed | 3 |
ace binding | 3 |
nested pcrs | 3 |
novel mammalian | 3 |
powerful biological | 3 |
sense rna | 3 |
rate increased | 3 |
numbers mh | 3 |
phylogenetic relationship | 3 |
novo software | 3 |
four categories | 3 |
antibody cr | 3 |
study demonstrated | 3 |
sybr green | 3 |
deltacoronavirus supports | 3 |
hours later | 3 |
chinese patient | 3 |
unported license | 3 |
based assays | 3 |
novel betacoronavirus | 3 |
mast cells | 3 |
glycosylation sites | 3 |
asian strains | 3 |
immunogenic complex | 3 |
april th | 3 |
local hospital | 3 |
infection route | 3 |
laboratory diagnostic | 3 |
one study | 3 |
sequences retrieved | 3 |
simian agent | 3 |
phagocytic cells | 3 |
pathogenic coronavirus | 3 |
also tested | 3 |
significantly inhibited | 3 |
sars outbreak | 3 |
human health | 3 |
also reported | 3 |
transmission route | 3 |
dpp residue | 3 |
protein suppressed | 3 |
provide evidence | 3 |
therapeutic effect | 3 |
viral isolation | 3 |
samples compared | 3 |
written consent | 3 |
lao pdr | 3 |
examination revealed | 3 |
cell activation | 3 |
truncation mutant | 3 |
recently described | 3 |
canine homolog | 3 |
economic losses | 3 |
see supplementary | 3 |
several reports | 3 |
disease status | 3 |
entry point | 3 |
specific neutralizing | 3 |
exhibited respiratory | 3 |
cov isolates | 3 |
astrovirus infections | 3 |
potential risk | 3 |
five years | 3 |
virus disease | 3 |
liver damage | 3 |
working group | 3 |
ecological changes | 3 |
genetic analysis | 3 |
histopathological examination | 3 |
observational study | 3 |
two highly | 3 |
pseudovirus entry | 3 |
mice died | 3 |
different viral | 3 |
sequencing data | 3 |
also susceptible | 3 |
might account | 3 |
may ultimately | 3 |
indian hajj | 3 |
virus production | 3 |
per well | 3 |
based pcr | 3 |
iii reverse | 3 |
faecal samples | 3 |
universal multiplex | 3 |
infections per | 3 |
antibodydependent enhancement | 3 |
virus zika | 3 |
bar compared | 3 |
within months | 3 |
ldh activities | 3 |
highly potent | 3 |
one family | 3 |
ctl responses | 3 |
wuhan outbreak | 3 |
ag mice | 3 |
strain usa | 3 |
innate immunosuppressive | 3 |
poultry populations | 3 |
bacterial pathogens | 3 |
initial denaturation | 3 |
clinical setting | 3 |
viral pneumonias | 3 |
universal influenza | 3 |
specific immune | 3 |
sample size | 3 |
human use | 3 |
protective antiviral | 3 |
barre syndrome | 3 |
us centers | 3 |
outbreak strains | 3 |
two times | 3 |
igg protein | 3 |
hcv infection | 3 |
mice injected | 3 |
reaction mix | 3 |
situ hybridization | 3 |
following primers | 3 |
pathogens including | 3 |
two individual | 3 |
aastv goose | 3 |
transmission rate | 3 |
minelute pcr | 3 |
sars epidemic | 3 |
glass opacity | 3 |
undiagnosed respiratory | 3 |
positive pcr | 3 |
ten days | 3 |
china national | 3 |
cell function | 3 |
first imported | 3 |
mountain view | 3 |
strains associated | 3 |
dpp gene | 3 |
coronavirus fusion | 3 |
medical university | 3 |
newly proposed | 3 |
american health | 3 |
antibody titers | 3 |
viral surface | 3 |
circulating ics | 3 |
written informed | 3 |
including sars | 3 |
invasive pneumococcal | 3 |
indirect immunofluorescence | 3 |
confluency reached | 3 |
mngs approach | 3 |
flow research | 3 |
dpp variants | 3 |
rna based | 3 |
second cohort | 3 |
zhejiang university | 3 |
lethal dose | 3 |
binding interface | 3 |
activation signal | 3 |
dendritic cell | 3 |
restriction sites | 3 |
antiviral monoclonal | 3 |
transposon system | 3 |
relatively small | 3 |
plasma samples | 3 |
china isolation | 3 |
viral genes | 3 |
rhesus macaques | 3 |
reactive protein | 3 |
monocytes macrophages | 3 |
rna negative | 3 |
commercial broilers | 3 |
sn chimera | 3 |
predicted germline | 3 |
specimens may | 3 |
specific diagnostic | 3 |
receptor ace | 3 |
antiviral gene | 3 |
strains tested | 3 |
performed according | 3 |
goslings showed | 3 |
fatal human | 3 |
specific monoclonal | 3 |
heavy chains | 3 |
one pathogen | 3 |
envelope protein | 3 |
clinical relevance | 3 |
different respiratory | 3 |
human receptor | 3 |
world monkey | 3 |
health problem | 3 |
seasonal influenza | 3 |
decreased gradually | 3 |
observation period | 3 |
adult respiratory | 3 |
patients hospitalized | 3 |
also recognized | 3 |
laboratory testing | 3 |
human viral | 3 |
sequence comparison | 3 |
acute liver | 3 |
high mutation | 3 |
bootstrap replicates | 3 |
complete protection | 3 |
antigen tests | 3 |
will help | 3 |
using multiplex | 3 |
viruses identified | 3 |
genome structure | 3 |
underlying risk | 3 |
independently associated | 3 |
broad neutralization | 3 |
envelope glycoproteins | 3 |
mers cases | 3 |
infected patient | 3 |
viral sequence | 3 |
wet market | 3 |
study indicates | 3 |
blood sample | 3 |
lowland gorillas | 3 |
epidemiological study | 3 |
studies indicate | 3 |
central nervous | 3 |
vaccine candidate | 3 |
study period | 3 |
human genome | 3 |
temporary left | 3 |
different lineage | 3 |
kenyan mers | 3 |
results support | 3 |
generic approach | 3 |
pcr based | 3 |
subsequent samples | 3 |
swab positives | 3 |
tubular epithelial | 3 |
pathogenic coronaviruses | 3 |
sequence identities | 3 |
among poultry | 3 |
constitutively active | 3 |
goose reovirus | 3 |
hajj pilgrimage | 3 |
sparrow deltacoronavirus | 3 |
pdcov spread | 3 |
serum neutralization | 3 |
important issue | 3 |
protein glycosylation | 3 |
mononuclear cells | 3 |
approach identifies | 3 |
virus envelope | 3 |
simple method | 3 |
troglodytes schweinfurthii | 3 |
dpp harboring | 3 |
emerging coronaviruses | 3 |
deltacoronavirus infection | 3 |
ii flow | 3 |
surveillance studies | 3 |
previously published | 3 |
low pathogenicity | 3 |
icu ward | 3 |
insufficient npcs | 3 |
respective dpp | 3 |
high concentration | 3 |
novel spdcov | 3 |
nucleotide level | 3 |
virus release | 3 |
virus sequences | 3 |
endoplasmic reticulum | 3 |
cellular responses | 3 |
lung parenchyma | 3 |
pteropine orthoreoviruses | 3 |
sequence ambiguities | 3 |
expressed dpp | 3 |
western hemisphere | 3 |
survived goslings | 3 |
virus titers | 3 |
poult enteritis | 3 |
two months | 3 |
analysed using | 3 |
observational data | 3 |
transcription factors | 3 |
whole virions | 3 |
ah ha | 3 |
many parts | 3 |
high morbidity | 3 |
like disease | 3 |
high rates | 3 |
family cluster | 3 |
diseases novel | 3 |
number hm | 3 |
viral cross | 3 |
key target | 3 |
natural reservoir | 3 |
elevated levels | 3 |
research software | 3 |
including deaths | 3 |
two chimpanzee | 3 |
foetal bovine | 3 |
results confirmed | 3 |
polymerase slippage | 3 |
molecular evolution | 3 |
single orf | 3 |
signal sequence | 3 |
respective control | 3 |
four subjects | 3 |
histopathological changes | 3 |
fetal bovine | 3 |
suspected cases | 3 |
key laboratory | 3 |
ape populations | 3 |
based neutralization | 3 |
blastx analysis | 3 |
recent common | 3 |
various types | 3 |
pdcov pcr | 3 |
culex mosquitoes | 3 |
coronavirus species | 3 |
pandemic virus | 3 |
irf phosphorylation | 3 |
poultry outbreaks | 3 |
pcr kit | 3 |
three highly | 3 |
np swabs | 3 |
poultry trade | 3 |
pathogenicity avian | 3 |
visceral gout | 3 |
technical support | 3 |
alt level | 3 |
dry coughing | 3 |
glycosylation motif | 3 |
virus structural | 3 |
ncov lab | 3 |
dynamic changes | 3 |
three structural | 3 |
years ago | 3 |
swine farms | 3 |
humoral response | 3 |
fowl adenovirus | 3 |
dpp signals | 3 |
six children | 3 |
blood mononuclear | 3 |
increased incidence | 3 |
another hospital | 3 |
nk cells | 3 |
protein cleavage | 3 |
arboviral disease | 3 |
strongly associated | 3 |
national natural | 3 |
described elsewhere | 3 |
automated thermal | 3 |
findings indicate | 3 |
zikv infections | 3 |
laboratories within | 3 |
rna positive | 3 |
infectious virions | 3 |
low shm | 3 |
sino biological | 3 |
facs diva | 3 |
derived variant | 3 |
medium containing | 3 |
conserved among | 3 |
also confirmed | 3 |
cambodian lbms | 3 |
fold dilutions | 3 |
dna polymerase | 3 |
competent vectors | 3 |
large numbers | 3 |
based mngs | 3 |
emerging arbovirus | 3 |
specific flaviviruses | 3 |
protein also | 3 |
exceptionally potent | 3 |
allantoic fluids | 3 |
fusion inhibitor | 3 |
viral fusion | 3 |
rna testing | 3 |
truncation mutants | 3 |
results also | 3 |
fruit bat | 3 |
transgen biotech | 3 |
family coronaviridae | 3 |
plate reader | 2 |
genome copy | 2 |
shanghai reported | 2 |
antibody production | 2 |
limited number | 2 |
affinity chromatography | 2 |
golgi intermediate | 2 |
viral titration | 2 |
human astroviruses | 2 |
similar results | 2 |
temporal trends | 2 |
cov pathogenesis | 2 |
first detected | 2 |
predispose chimpanzees | 2 |
fold serial | 2 |
commonly used | 2 |
amniotic fluid | 2 |
inducible protein | 2 |
unexplained respiratory | 2 |
fresh tissues | 2 |
cell monolayers | 2 |
two major | 2 |
peak influenza | 2 |
three camel | 2 |
diarrhoea syndrome | 2 |
metagenomic next | 2 |
additional respiratory | 2 |
rad laboratories | 2 |
past five | 2 |
least different | 2 |
goose gout | 2 |
increased risk | 2 |
cells also | 2 |
horse remained | 2 |
infected ducks | 2 |
two new | 2 |
virus pneumonia | 2 |
recently also | 2 |
virus strains | 2 |
mild respiratory | 2 |
artery disease | 2 |
climate change | 2 |
per group | 2 |
kidney tissues | 2 |
immune deficiency | 2 |
blood oxygen | 2 |
anhui province | 2 |
harbor diverse | 2 |
global public | 2 |
tmb substrate | 2 |
person transmission | 2 |
january th | 2 |
astrovirus causing | 2 |
based immunotherapy | 2 |
arterial pressure | 2 |
inhibits type | 2 |
software inc | 2 |
rlr signaling | 2 |
since february | 2 |
lower sensitivity | 2 |
ncov viral | 2 |
hia titre | 2 |
neurological cases | 2 |
made automatically | 2 |
hepaciviral infection | 2 |
mononucleotide polymeric | 2 |
deletion mutant | 2 |
important human | 2 |
igg fc | 2 |
proposed model | 2 |
individual mutation | 2 |
serological detection | 2 |
candidate therapeutics | 2 |
higher mortality | 2 |
structural features | 2 |
enters cells | 2 |
effective strategy | 2 |
representative sars | 2 |
clinical presentations | 2 |
low immunogenicity | 2 |
ecori xhoi | 2 |
develop novel | 2 |
tb lymphocyte | 2 |
epitope density | 2 |
times higher | 2 |
outside africa | 2 |
mean arterial | 2 |
also important | 2 |
fc region | 2 |
substantial economic | 2 |
institut pasteur | 2 |
laboratory training | 2 |
recent emergence | 2 |
reverse genetics | 2 |
extraction kit | 2 |
purulent sputum | 2 |
pneumonia caused | 2 |
human survivors | 2 |
low mortality | 2 |
intrinsic antibodydependent | 2 |
mouse sera | 2 |
viruses may | 2 |
national center | 2 |
hku strain | 2 |
receptorbinding domain | 2 |
polyclonal igg | 2 |
fc antibody | 2 |
milder symptoms | 2 |
fluorescence intensity | 2 |
cambodian live | 2 |
parametric variables | 2 |
complete genomic | 2 |
containing fetal | 2 |
sequences within | 2 |
flu rsv | 2 |
many patients | 2 |
mice influenza | 2 |
confirmed mers | 2 |
stop codon | 2 |
biochemical properties | 2 |
new clinical | 2 |
institutional review | 2 |
every epidemic | 2 |
healthy adults | 2 |
studies conducted | 2 |
infant macaques | 2 |
laboratory capabilities | 2 |
less pronounced | 2 |
fresh medium | 2 |
infection influenza | 2 |
hand washing | 2 |
etiological agents | 2 |
swabs detection | 2 |
positive cells | 2 |
sensitive detection | 2 |
colloidal gold | 2 |
escherichia coli | 2 |
species tropism | 2 |
luc reporter | 2 |
infecting humans | 2 |
cov failed | 2 |
close contacts | 2 |
culex tritaeniorhynchus | 2 |
computed using | 2 |
samples included | 2 |
carriage rates | 2 |
newly described | 2 |
collecting saliva | 2 |
remained positive | 2 |
provides protection | 2 |
fluid samples | 2 |
assay also | 2 |
na inhibitors | 2 |
rnadependent rna | 2 |
fatal visceral | 2 |
immune serum | 2 |
receptor interaction | 2 |
repeated testing | 2 |
neutralization assays | 2 |
synthesis kit | 2 |
functional domains | 2 |
disinfectant gel | 2 |
neutralizing humoral | 2 |
used instead | 2 |
reactive oxygen | 2 |
sort within | 2 |
orthoreovirus species | 2 |
usa illinois | 2 |
coronavirus diversity | 2 |
transfected cells | 2 |
initial tree | 2 |
novel circular | 2 |
either tested | 2 |
lethal cases | 2 |
adapt immunity | 2 |
highly expressed | 2 |
arterial oxygen | 2 |
states possessed | 2 |